Accordingly, we conducted an international, adaptive, controlled platform randomized clinical trial to evaluate whether P2Y12 inhibition increased days alive and free of organ support, the composite of survival to hospital discharge and days free of cardiovascular or respiratory organ support through day 21, in critically ill patients hospitalized for COVID-19. Here, P2RY12 is linked to COVID-19.